Scientists Identify Molecular Signature for Leukemia Stem Cells

Mar 10, 2009

Scientists studying chronic myeloid leukemia, more commonly known as CML, are one step closer to decoding the “genetic signature” of stem cells in this disease. They’ve identified a marker in a tiny but powerful subset of leukemia cells that could enable scientists to halt cancer cell growth in CML, and perhaps in other forms of cancer.

Their work is published in this week’s . Among the authors is Francis J. Giles, M.B., M.D., professor and chief of hematology and at The University of Texas Health Science Center at San Antonio. Dr. Giles also is deputy director of the Therapy and Research Center at the UT Health Science Center, and director of the CTRC’s Institute for Drug Development.

About 4,500 new cases of chronic myeloid leukemia were diagnosed in 2006, mostly in adults. The disease, marked by massive growth of in the body, results from a change in the DNA of a stem cell in the bone marrow. The stem cell’s changed DNA gives the malignant (cancerous) cell an advantage over normal in terms of growth and survival. Scientists do not yet understand what produces this change in the DNA, which is not present at birth.

“Well over 90 percent of patients with CML improve with the front-line and second-line treatments, imatinib and nilotinib,” says Dr. Giles, a leading developer of nilotinib, approved in 2007 by the Food and Drug Administration. “But if you’re among those who don’t respond or you lose your prior response, this research finding is very important.

“We believe stem cells are the obstacle to a cure for leukemia. If we’ve killed nearly all of a patient’s cancer cells, but we haven’t killed the stem cells, we haven’t cured the patient. A marker helps us find the elusive stem cells, quantify them, and follow their behavior in patients. Then we can see how the stem cell behavior differs from that of other more mature cancer cells, and develop stem cell-directed new therapies.”

Dr. Giles says this marker, an abnormality in the Wnt/ß catenin self-renewal pathway, may enable scientists to develop a test that could be given to leukemia patients following treatment to make sure the stem cells have been eliminated. Another potential application is to test drugs under development in San Antonio and elsewhere to change the stem cells’ instructions.

“Perhaps we can tell the stem cells to ignore their previous instructions and get them to change into another type of cancer cell that we know how to kill,” Dr. Giles theorizes.

Much of the laboratory work that identified the abnormality was conducted at Moores Cancer Center at the University of California San Diego. Aside from Dr Giles’ role in the design and conduct of the research, CTRC patients with CML contributed samples of blood and bone marrow, and the CTRC’s Institute for Drug Development is testing drugs that may alter cancer stem cell function in the leukemias or in solid tumors.

Provided by University of Texas Health Science Center at San Antonio

Explore further: UC San Diego, UC San Francisco launch new cancer cell mapping initiative

add to favorites email to friend print save as pdf

Related Stories

Drug has ability to cure type of leukemia

Oct 03, 2007

In people with chronic myeloid leukemia (CML), the drug Imatinib has been shown to drive cancer into remission, but the disease often returns when treatment is stopped. New research by UC Irvine scientists indicates that ...

UCLA researchers identify leukemia stem cells

May 27, 2008

Stem cell researchers at UCLA have identified a type of leukemia stem cell and uncovered the molecular and genetic mechanisms that cause a normal blood stem cells to become cancerous.

Recommended for you

Cancer fear can impact screening uptake

5 hours ago

People who worry about cancer are more likely to want to get screened for colon cancer, but feeling uncomfortable at the thought of cancer makes them less likely to actually go for the test, finds new UCL-led ...

Elucidating the origin of MDR tuberculosis strains

8 hours ago

A study has focused on the evolutionary history of the mycobacterium that causes tuberculosis, and more specifically on the Beijing lineage associated with the spread of multidrug resistant forms of the disease ...

Mexico escalating the fight against breast cancer

9 hours ago

On Avenue San Fernando, a tree-lined street crowded with food stands, the new wing of Mexico's flagship cancer hospital gleams like a silver airplane. Barely a year old, the light-filled structure attached to the National ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.